Omega-3 and Aspirin in Periodontal Regeneration

The Effect of Host Response Modulation Therapy (Omega 3 Plus Low-dose Aspirin) as an Adjunctive Treatment of Chronic Periodontitis (Clinical and Biochemical Study)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01113528

Acronym

Enrollment

Registered

2010-04-30

Start date

2009-11-30

Completion date

2010-05-31

Last updated

2010-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Disease

Keywords

Bone allograft, IL-1, IL-10, periodontal regeneration, omega-3, aspirin

Brief summary

To evaluate the efficacy of systemic administration of omega 3 PUFA plus low dose aspirin as an adjunctive therapy to regenerative modality of grade II furcation defects in periodontitis patients.

Detailed description

In this study, we tested the hypothesis that the administration of omega 3 PUFA plus low dose aspirin would augment the results following regenerative therapy of furcation defects in chronic periodontitis patients.

Interventions

OTHERRegenerative therapy (omega 3 PUFA plus low dose aspirin)

Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin

DRUGSugar pill

3 times daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

35 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* suffering moderate to sever chronic periodontitis and displaying at least a single grade II furcation defect according to Glickman's classification 1953, determined by both clinical and radiographic examinations; * free from systemic diseases known to influence the periodontal condition and not receiving any medication known to affect the periodontal status; * have not receive any periodontal therapy for a minimum of 6 months prior to the study.

Exclusion criteria

* Known hypersensitivity or allergy to one of the used medications * Pregnancy or lactation * Heavy smoking (more than 10cigarretes/day) * History of alcohol abuse * Participation in other clinical trials

Design outcomes

Primary

Measure	Time frame	Description
Cytokine levels	six months	Interleukin-1 beta Interleukin-10

Secondary

Measure	Time frame	Description
Gingival inflammation	six months	plaque index Gingival index Gingival bleeding index
Healing after regenerative therapy	six months	Probing pocket depth Clinical attachment level

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026